Country Trust Bank Has $136,000 Stake in Pfizer Inc. (NYSE:PFE)

Country Trust Bank lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 46.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,700 shares of the biopharmaceutical company’s stock after buying an additional 1,500 shares during the quarter. Country Trust Bank’s holdings in Pfizer were worth $136,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Bellevue Group AG lifted its stake in Pfizer by 139.3% in the fourth quarter. Bellevue Group AG now owns 22,868 shares of the biopharmaceutical company’s stock valued at $658,000 after buying an additional 13,313 shares during the period. Wasatch Advisors LP increased its stake in shares of Pfizer by 21.0% in the 4th quarter. Wasatch Advisors LP now owns 167,300 shares of the biopharmaceutical company’s stock valued at $4,817,000 after acquiring an additional 29,000 shares in the last quarter. MGO One Seven LLC lifted its position in shares of Pfizer by 43.0% during the 4th quarter. MGO One Seven LLC now owns 120,715 shares of the biopharmaceutical company’s stock valued at $3,475,000 after acquiring an additional 36,316 shares during the period. Icon Wealth Advisors LLC acquired a new stake in Pfizer in the fourth quarter worth $479,000. Finally, Jacobi Capital Management LLC raised its holdings in shares of Pfizer by 3.3% during the fourth quarter. Jacobi Capital Management LLC now owns 120,810 shares of the biopharmaceutical company’s stock valued at $3,478,000 after purchasing an additional 3,904 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research reports. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Wells Fargo & Company raised their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. UBS Group upped their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Finally, Barclays upped their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Stock Down 0.1 %

Pfizer stock opened at $29.18 on Wednesday. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $33.92. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The firm’s 50-day simple moving average is $29.14 and its 200 day simple moving average is $28.33. The stock has a market cap of $165.35 billion, a PE ratio of -486.33, a price-to-earnings-growth ratio of 1.23 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.67 EPS. Research analysts predict that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.